CN101032516A - Preparing technique of zeolite type quick hemostasis agent - Google Patents
Preparing technique of zeolite type quick hemostasis agent Download PDFInfo
- Publication number
- CN101032516A CN101032516A CN200610067266.3A CN200610067266A CN101032516A CN 101032516 A CN101032516 A CN 101032516A CN 200610067266 A CN200610067266 A CN 200610067266A CN 101032516 A CN101032516 A CN 101032516A
- Authority
- CN
- China
- Prior art keywords
- zeolite
- hemostasis
- hemostasis agent
- quick hemostasis
- hemorrhage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910021536 Zeolite Inorganic materials 0.000 title claims abstract description 32
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 239000010457 zeolite Substances 0.000 title claims abstract description 32
- 239000002874 hemostatic agent Substances 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 238000012856 packing Methods 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims description 9
- 238000010298 pulverizing process Methods 0.000 claims description 8
- 230000003749 cleanliness Effects 0.000 claims 1
- 230000023597 hemostasis Effects 0.000 abstract description 15
- 238000010438 heat treatment Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 230000023555 blood coagulation Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract 1
- 208000032843 Hemorrhage Diseases 0.000 description 24
- 239000002245 particle Substances 0.000 description 13
- 230000000025 haemostatic effect Effects 0.000 description 12
- 206010052428 Wound Diseases 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 206010053567 Coagulopathies Diseases 0.000 description 6
- 230000035602 clotting Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000007873 sieving Methods 0.000 description 5
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229940030225 antihemorrhagics Drugs 0.000 description 3
- 238000009413 insulation Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000000498 ball milling Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 238000009461 vacuum packaging Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 208000035992 Postmortem Changes Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 239000009306 yunnan baiyao Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention discloses process of preparing fast zeolite hemostat. The process includes crushing zeolite, production under optimized temperature, vacuum degree and heating period, and packing in a clean condition. The fast zeolite hemostat is suitable for hemostasis of medium and serious opened wound, and has excellent effect of promoting blood coagulation. The present invention may be used widely in hemostasis.
Description
One, technical field
The present invention relates to the zeolite is the technology of feedstock production quick hemostasis agent, belongs to the hemostatic material in medical use technical field.
Two, background technology
The injured people who dies in various accidents or on the battlefield, half is arranged is dead because of severe loss of blood before arriving at the medical center.According to the data statistics of repeatedly war war wound, have 30%～60% to fall in battle be because severe loss of blood, and the wounded that send to treatment mechanism topmost cause of death in back 24 hours of wound also is a severe loss of blood.Treatment of war wound studies show that, if the wounded can access treatment with interior in 1～3 hour after wound, and hemorrhage can being effectively controlled, percentage of killed in action and percentage of died of wound will reduce greatly so, and the treatment of war wound level will improve greatly.Now, adopt quick hemostasis agent to realize this goal.
U.S. army has just obtained the quick hemostasis agent (trade name: QuickClot), equipped to quartering at the bay and attacked Irak US soldiers of FDA approval in May, 2002.U.S. army has just used QuickClot, effect to make us very satisfied in Afghan military operation.The packing that quick hemostasis agent is easy to carry and uses can one-handed performance.Be specially adapted to the hemostasis of the open wound of moderate, severe.
China reaches more than 10 ten thousand people because of various accidents cause the traumatic patient of severe haemorrhage every year, owing to failing quick-acting haemostatic powder in the time that closely may lack, causes dead ratio high; Quick hemostasis agent also can be widely used in the hemorrhagic wound that various accidents cause at time of peace, also is the important military articles for use.So, at China's development, production quick hemostasis agent the important clinical meaning is arranged, can significantly reduce mortality rate, produce good social benefit.Simultaneously, produce quick hemostasis agent and also can bring good economic benefits.
The action principle of quick hemostasis agent is pure physical property, and quick hemostasis agent is the zeolite of certain particle size scope, and this zeolite is through special handling.Thereby zeolite can cause the platelet of wound location and thrombin to concentrate the normal blood clotting process of human body of quickening.Twine pressurization or directly push in conjunction with aseptic binder, quick hemostasis agent can significantly reduce losing of blood, significantly improves the survival rate of severe trauma.
At present, domesticly be used for, the quick hemostasis agent product of severe bleeding, belong to blank.First aid hemorrhage commonly used has tourniquet, gauze and YUNNAN BAIYAO, they in, the quick-acting haemostatic powder effect of severe bleeding is very limited, therefore, research can be used for the quick hemostasis agent of urgent rescue, in can saving, severe bleeding patient life.Quick hemostasis agent is used for army, police, fire fighter, first-aid personnel, medical personnel and domestic hemostasis first aid, and rescue of battlefield, also can play a role in vital emergent event such as earthquake, blast, mine accident etc.
There is no at present patent and relevant report both at home and abroad about zeolite type hemorrhage production technology.United States Patent (USP) 4,822, in 349 touch upon in the zeolite type hemorrhage production technology about the problem of heating in vacuum dehydration.But this disclosing do not relate to concrete processing parameter, more do not have the manufacturing condition of optimization, is far from being enough to the actual production hemorrhage, needs further concrete production Technology parameter, just can produce.Particularly be optimized test, the process conditions that are optimized, to obtaining high-quality hemorrhage, all cause the pass to reducing production costs important.As, suitable heating-up temperature scope, heat time heating time, vacuum ranges etc. are necessary to producing qualified hemorrhage product.For example, heating-up temperature is 1000 degrees centigrade, will cause zeolite crystal structure to destroy, and does not also just have anastalsis thereby lose absorbent function.Again for example, heating-up temperature is that 100 degree then are difficult to make water content to be reduced to needed degree, thereby reduces haemostatic effect greatly.In addition, heat time heating time is oversize, vacuum is too high all can increase energy consumption, causes production cost to increase and unnecessary energy waste.Therefore, good up-to-standard hemorrhage is vital to producing haemostatic effect to select suitable temperature range, heat time heating time, vacuum ranges.
The hemostasis trial method: every experiment rabbit is implemented anesthesia, be fixed on the operating-table, surgical exposure femoral artery and lateral dissection 3/4 make it freely spray blood 10 seconds, use the quick hemostasis agent hemostasis then.Observe its bleeding stopping period.
Dried weightlessness records method: get this product, accurately to the crucible claim surely, in the vacuum drying oven, 200 ℃, vacuum keeps 40min less than 200Pa, is cooled to room temperature under vacuum state then, accurately claims surely, calculates by formula (1), and its result should meet 3.5 regulation.
In the formula: X-does weightless, %;
W
1-be the crucible quality, g;
W
2Crucible behind the-vacuum drying and hemorrhage gross weight, g;
The W-sample quality, g.
The production technology of the quick hemostasis agent of the present invention's design is simple, and floor space is very little, does not have three-waste pollution, and equipment investment is very little, carries out suitability for industrialized production easily.
Three, summary of the invention
The present invention proposes a kind of is the technology of feedstock production quick hemostasis agent with the zeolite, and this technology is simple, easy to operate, controllability is strong, with short production cycle, cost is low, pollution-free.
Preparation method of the present invention mainly realizes by following steps:
(1) pulverizing of zeolite raw material: it is brittle material that the present invention adopts zeolite, and for obtaining the granule that better haemostatic effect is arranged of certain particle size scope, raw material at first will be through pulverizing.The present invention selects for use ball mill to pulverize, and can satisfy the granularity requirements of product, and dustless.
(2) sieve: sieving is in order to remove larger particles and fine powder, to obtain the moderate granule of granularity.Material after pulverizing is put on the VibrationsifterwithElectromagnetism, crossed 14～30 mesh sieves earlier, sieve removes larger particles; After 80～140 mesh sieves, sieve removes fine powder.
(3) the dry and cooling of vacuum high-temperature
The moderate sieve particle of granularity that obtains after sieving is tiled on the stainless steel disc, puts into vacuum drying oven again, homoiothermic degree to 150～250 ℃, vacuum drying 1～2 hour, logical water quench material in cooling tube again.
(4) vacuum packaging
Quick hemostasis agent of the present invention is the sterile vacuum packing.In the air cleaning rank is that 1～100,000 grade toilet carries out the last packaging process of this product.
The haemostatic effect difference of varigrained zeolite granular, so, carried out the hemostasis trial of different grain size hemorrhage.The heating-up temperature of producing hemorrhage be 150 ℃, pressure less than 500Pa, 250 ℃ of temperature maintenance, insulation is 2 hours under the vacuum.To sieving of zeolite granular, obtain the zeolite granular that different-grain diameter distributes, the zeolite granular that distributes with resulting different-grain diameter carries out hemostasis trial respectively.By the particle size distribution difference, be divided into 3 groups:＞24 orders, 24～140 orders,＜140 orders carry out hemostasis trial respectively with the zeolite granular of 3 kinds of particle size distribution, and laboratory animal is a large ear rabbit, 18 altogether, divides 3 groups, 6 every group.Table 1 provides the hemostasis trial result of different grain size zeolite granular, and by table 1 as seen, granularity is greater than 24 orders, and its average clotting time is longer, and haemostatic effect is bad.If granularity is less than 140 orders, its average clotting time is also long, and haemostatic effect is poor.When granularity was 24～140, average clotting time was the shortest, and haemostatic effect is best.
The hemostasis trial of table 1 different grain size hemorrhage
| Granularity (order) | ＞24 | 24～140 | ＜140 |
| Average clotting time (second) thermal discharge | 39.23 it is moderate | 26.01 it is moderate | 42.14 it is violent |
The dried weightlessness of hemorrhage has considerable influence to the haemostatic effect of hemorrhage, so carried out the hemostasis trial of the weightless hemorrhage of different dry.The heating-up temperature of producing hemorrhage is 250 ℃, and pressure is less than 500Pa, and 250 ℃ of temperature maintenance are incubated 1 hour under the vacuum.The granularity of zeolite is 24～140 orders.Zeolite granular is done weightlessness adjust, make the zeolite granular moisture absorption, change it and do weightlessness, make and do the setting value that weightlessness reaches test.Carry out hemostasis trial with the weightless hemorrhage of different dry.Laboratory animal is a large ear rabbit, amounts to 20, divides 5 groups, and 4 every group are carried out hemostasis trial, and result of the test sees Table 2.By table 2 as seen, when Zeolite hemostatic dried bean noodles weightlessness greater than 3% the time, average cruor time extending is 3% and 3.5% o'clock corresponding to dried weightlessness, on average clotting time was respectively 39.25 seconds and 55.09 seconds, haemostatic effect is relatively poor, has not had the effect of quick-acting haemostatic powder.This prompting, when doing weightless surpassing when a certain amount of, the anastalsis of hemorrhage is less.
The hemostasis trial of the weightless hemorrhage of table 2 different dry
| Do weightless | 0.9％ | 1.5％ | 2.5％ | 3.0％ | 3.5％ |
| Average clotting time (second) | 24.32 | 26.21 | 26.54 | 39.25 | 45.09 |
The specific embodiment
Embodiment 1
Take by weighing about 1000g zeolite raw material, put into ball mill pulverizer, ball-milling medium is steel ball, particle diameter 5mm, and rotating speed 800r/min grinds 30min, takes out the granule after pulverizing.Material after pulverizing is put on the VibrationsifterwithElectromagnetism, crossed 14 mesh sieves earlier, sieve removes larger particles; After 140 mesh sieves, sieve removes fine powder; The moderate sieve particle of granularity that obtains after sieving is tiled in (the about 5mm of thickness) on the stainless steel disc, put into 32 dish vacuum drying ovens again, homoiothermic degree to 150 ℃, opening vacuum pump makes pressure less than 500Pa, under the vacuum, 150 ℃ the insulation 2 hours, logical water quench in cooling tube makes temperature of charge reduce to room temperature again, at last vacuum-packed finished product and be stored in cool place, dry place in the sterile chamber.
Embodiment 2
Take by weighing about 1000g zeolite raw material, put into ball mill pulverizer, ball-milling medium is steel ball, particle diameter 5mm, and rotating speed 500r/min grinds 30min, takes out the granule after pulverizing.Material after pulverizing is put on the VibrationsifterwithElectromagnetism, crossed 20 mesh sieves earlier, sieve removes larger particles; After 80 mesh sieves, sieve removes fine powder; The moderate sieve particle of granularity that obtains after sieving is tiled in (the about 5mm of thickness) on the stainless steel disc, put into 32 dish vacuum drying ovens again, homoiothermic degree to 250 ℃, opening vacuum pump makes pressure less than 500Pa, under the vacuum, 250 ℃ the insulation 1.0 hours, logical water quench in cooling tube makes temperature of charge reduce to room temperature again, at last vacuum-packed finished product and be stored in cool place, dry place in the sterile chamber.
Claims (3)
1. be the method for feedstock production quick hemostasis agent with the zeolite, may further comprise the steps:
(1) zeolite is pulverized;
(2) zeolite of pulverizing is heated to 150 ℃～250 ℃, evacuation keeps being cooled to room temperature after 0.5～2 hour;
(3) at cleanliness class be 1～100,000 grade toilet packing, get product.
2. the quick hemostasis agent described in the claim 1, its granularity is the zeolite powder between 14～140 mesh sieves.
3. the zeolite powder described in the claim 2, it does weightless less than 3%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100672663A CN100571711C (en) | 2006-03-09 | 2006-03-09 | A kind of preparation technology of zeolite type quick hemostasis agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100672663A CN100571711C (en) | 2006-03-09 | 2006-03-09 | A kind of preparation technology of zeolite type quick hemostasis agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101032516A true CN101032516A (en) | 2007-09-12 |
| CN100571711C CN100571711C (en) | 2009-12-23 |
Family
ID=38729382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100672663A Expired - Fee Related CN100571711C (en) | 2006-03-09 | 2006-03-09 | A kind of preparation technology of zeolite type quick hemostasis agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100571711C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102000111A (en) * | 2010-12-23 | 2011-04-06 | 范杰 | Preparation method of emergency survival hemostatic based on natural zeolite in Jinyun of Zhejiang |
| CN101455855B (en) * | 2009-01-06 | 2013-03-06 | 浙江大学 | Method for increasing Quickclot haemostatic performance |
-
2006
- 2006-03-09 CN CNB2006100672663A patent/CN100571711C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101455855B (en) * | 2009-01-06 | 2013-03-06 | 浙江大学 | Method for increasing Quickclot haemostatic performance |
| CN102000111A (en) * | 2010-12-23 | 2011-04-06 | 范杰 | Preparation method of emergency survival hemostatic based on natural zeolite in Jinyun of Zhejiang |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100571711C (en) | 2009-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jiang et al. | Antimicrobial, antioxidant and physical properties of chitosan film containing Akebia trifoliata (Thunb.) Koidz. peel extract/montmorillonite and its application | |
| JP7061811B2 (en) | Iron-containing oxide / nanokaolin composite hemostatic agent and its manufacturing method | |
| CN102846698B (en) | Wall-broken radix tetrastigme oral decoction pieces | |
| Chen et al. | Rapid hemostasis accompanied by antibacterial action of calcium crosslinking tannic acid-coated mesoporous silica/silver Janus nanoparticles | |
| CN101104080B (en) | Zeolite hemostatic dressings and preparation method and application thereof | |
| WO2008034304A1 (en) | Nanometer mesoporous silica-based xerogel styptic material and its preparing process and application | |
| CN101596207A (en) | Be used for rapid hemostatic Pharmaceutical composition and preparation method | |
| CN100571711C (en) | A kind of preparation technology of zeolite type quick hemostasis agent | |
| CN112168803A (en) | Ganoderma spore powder capsule and its processing method | |
| CN101164583B (en) | Compound formulation for the treatment of epithelial erosion and preparation method thereof | |
| CN105561370A (en) | Novel hemostatic material and preparation method thereof | |
| CN104719914B (en) | A kind of composition for improving gastrointestinal function and preparation method thereof | |
| CN104490964A (en) | Preparation method of active pseudo-ginseng ultramicro powder | |
| CN104189110B (en) | A kind of Chinese medicine composition for the treatment of influenza and preparation method thereof | |
| CN107158448A (en) | A kind of medical bio hemostatic material and preparation method thereof | |
| JP7320078B2 (en) | Biocellulose fiber, hemostatic dressing containing same and related applications | |
| CN113616847B (en) | Calamine hemostatic compound based on Y molecular sieve carrier and preparation thereof | |
| CN104524222A (en) | Traditional Chinese medicine for promoting wound healing | |
| Wang et al. | Extraction kinetic model of polysaccharide from Codonopsis pilosula and the application of polysaccharide in wound healing | |
| CN105533392A (en) | Traditional Chinese medicinal material freeze-drying processing method | |
| KR101196959B1 (en) | Tablet manufacturing method of silkworm power | |
| Xu et al. | Hemostatic effect of macroporous polysaccharides composite hemostatic materials on small-artery severed injury | |
| CN102357258A (en) | Preparation method of dressing for treating burn combined with moist burn cream | |
| CN111298190A (en) | Hemostatic material for infants and preparation method thereof | |
| CN114129765B (en) | Hemostatic material and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 266061 Shandong Province, Qingdao city Laoshan District Songling Road No. 69 Patentee after: Qingdao University of Science & Technology Address before: 266042 Zhengzhou Road, Sifang District, Shandong, China, No. 53, No. Patentee before: Qingdao University of Science & Technology |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091223 Termination date: 20110309 |